Eric Swayze Sells 1,194 Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Stock

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) EVP Eric Swayze sold 1,194 shares of Ionis Pharmaceuticals stock in a transaction dated Tuesday, November 12th. The stock was sold at an average price of $37.92, for a total transaction of $45,276.48. Following the transaction, the executive vice president now directly owns 33,713 shares in the company, valued at $1,278,396.96. This trade represents a 3.42 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Eric Swayze also recently made the following trade(s):

• On Wednesday, October 16th, Eric Swayze sold 53 shares of Ionis Pharmaceuticals stock. The stock was sold at an average price of $38.31, for a total value of $2,030.43.

Ionis Pharmaceuticals Stock Performance

NASDAQ:IONS traded down $1.72 during trading hours on Friday, reaching $35.51. The company had a trading volume of 248,925 shares, compared to its average volume of 1,309,919. The stock has a 50-day moving average of $39.87 and a two-hundred day moving average of $42.80. Ionis Pharmaceuticals, Inc. has a one year low of $35.37 and a one year high of $54.44. The company has a debt-to-equity ratio of 1.86, a quick ratio of 8.82 and a current ratio of 8.91.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on the stock. Guggenheim cut their target price on shares of Ionis Pharmaceuticals from $70.00 to $65.00 and set a “buy” rating on the stock in a research note on Wednesday, October 9th. Leerink Partners raised shares of Ionis Pharmaceuticals from a “market perform” rating to an “outperform” rating and boosted their price objective for the company from $53.00 to $62.00 in a research note on Wednesday, July 24th. Leerink Partnrs upgraded Ionis Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, July 24th. The Goldman Sachs Group boosted their target price on Ionis Pharmaceuticals from $33.00 to $37.00 and gave the stock a “sell” rating in a research report on Friday, August 2nd. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $70.00 target price on shares of Ionis Pharmaceuticals in a research note on Thursday, September 26th. Two analysts have rated the stock with a sell rating, five have assigned a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Ionis Pharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $60.65.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the stock. GAMMA Investing LLC boosted its position in shares of Ionis Pharmaceuticals by 83.9% during the third quarter. GAMMA Investing LLC now owns 664 shares of the company’s stock worth $27,000 after purchasing an additional 303 shares in the last quarter. nVerses Capital LLC acquired a new stake in Ionis Pharmaceuticals during the 2nd quarter worth approximately $29,000. Itau Unibanco Holding S.A. bought a new stake in shares of Ionis Pharmaceuticals during the second quarter worth $37,000. Mather Group LLC. raised its holdings in shares of Ionis Pharmaceuticals by 35.8% during the second quarter. Mather Group LLC. now owns 911 shares of the company’s stock worth $39,000 after acquiring an additional 240 shares during the period. Finally, Capital Performance Advisors LLP bought a new stake in Ionis Pharmaceuticals in the 3rd quarter valued at $40,000. Institutional investors own 93.86% of the company’s stock.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.